Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)-associated diseases.

152 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

[1]  T. Portis,et al.  Epstein-Barr Virus LMP2A Interferes with Global Transcription Factor Regulation When Expressed during B-Lymphocyte Development , 2003, Journal of Virology.

[2]  R. Longnecker,et al.  Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease. , 2002, Antiviral research.

[3]  S. Hamilton-Dutoit,et al.  Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma , 2002, Oncogene.

[4]  H. Stein,et al.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. , 2002, Blood.

[5]  H. Stein,et al.  Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. , 2002, Blood.

[6]  P. Farmer,et al.  The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.

[7]  J. Stein,et al.  Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. , 2002, The Journal of nutrition.

[8]  H. Stein,et al.  Activated Notch 1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma , 2002 .

[9]  R. Longnecker,et al.  LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. , 2001, Virology.

[10]  D. Thorley-Lawson,et al.  Epstein-Barr virus: exploiting the immune system , 2001, Nature Reviews Immunology.

[11]  R. Longnecker,et al.  Epstein-Barr Virus Latent Membrane Protein 2a (Lmp2a) Employs the Slp-65 Signaling Module , 2001, The Journal of experimental medicine.

[12]  R. Longnecker,et al.  PY Motifs of Epstein-Barr Virus LMP2A Regulate Protein Stability and Phosphorylation of LMP2A-Associated Proteins , 2001, Journal of Virology.

[13]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[14]  R. Longnecker,et al.  Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. , 2001, Immunity.

[15]  R. Longnecker,et al.  The LMP2A ITAM Is Essential for Providing B Cells with Development and Survival Signals In Vivo , 2000, Journal of Virology.

[16]  R. N. Harty,et al.  WW- and SH3-domain interactions with Epstein-Barr virus LMP2A. , 2000, Experimental cell research.

[17]  R. Longnecker,et al.  The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. , 2000, Virology.

[18]  R. Longnecker,et al.  Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? , 2000, Advances in cancer research.

[19]  L. Staudt,et al.  Reed-Sternberg cell genome expression supports a B-cell lineage. , 1999, Blood.

[20]  E. Kremmer,et al.  Tyrosine 112 of Latent Membrane Protein 2A Is Essential for Protein Tyrosine Kinase Loading and Regulation of Epstein-Barr Virus Latency , 1998, Journal of Virology.

[21]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[22]  K. Rajewsky,et al.  In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death , 1997, Cell.

[23]  R. Longnecker,et al.  The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. , 1997, Virology.

[24]  E. Kieff.  Epstein-Barr virus and its replication , 1996 .

[25]  G. Niedobitek.  The role of Epstein-Barr virus in the pathogenesis of Hodgkin's disease. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  E. Kieff,et al.  Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. , 1995, Immunity.

[27]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes , 1993, Journal of virology.

[28]  E. Kieff,et al.  An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases , 1992, Journal of virology.

[29]  T. Ooka.  The molecular biology of Epstein-Barr virus. , 1985, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.